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Retinoids and rexinoids in lung cancer biology and therapy
Khuri, Fadlo R. 
Emory Winship Cancer Institute, Atlanta, GA, USA
Retinoids are natural or synthetic vitamin A derivatives that have long 
been implicated in an important role in cancer biology and preven-
tion. Studies show that vitamin A deprivation can lead to an increased 
carcinogenesis in the lung and upper aerodigestive tract. Early trials by 
Hong et al of a high dose synthetic retinoid, isotretinoin, showed that 
this agent could reverse early to intermediate head and neck prema-
lignancy, and that high doses of isotretinoin given for one year in 8 
patients treated deﬁnitively for an advanced head and neck primary 
tumors prevented second primary tumors (SPTs) for a period of two to 
three years after cessation of retinoid therapy. However, high doses of 
isotretinoin were intolerable to most patients, and a larger randomized 
trial of isotretinoin in head and neck squamous cell cancer failed to re-
produce the earlier data, with no evidence of reduction in SPTs. More-
over, this agent was ineffective at tolerable doses in preventing SPTs in 
patients treated for early stage non-small cell lung cancer (NSCLC).
Both retinoids and rexinoids, and in fact, all synthetic vitamin A 
compounds function by binding to cograte retinoid nuclear receptors, 
the retinoic acid receptors (RARs), and retinoid X receptors (RXRs). 
Synthetic rexinoids were ﬁrst synthesized in the early 1990s, given the 
diverse binding partners (RAR/RXR or LXR/RXR heterodimers, for 
example or RXR/RXR homodimers) that these compounds can bind to. 
The rexinoid, bexarotene, was introduced into clinical trials in the early 
1990s and was shown to produce prolonged stabilization in patients 
with NSCLC. Subsequent combinations with standard front line che-
motherapy for NSCLC appeared promising with longer than expected 
median survivals in the absence of more pronounced responses. Two 
phase III trials of bexarotene with front line chemotherapy failed to 
show superiority over the standard chemotherapy arms. However, in 
those patients who had grade 3 hypertriglyceridemia due to bexaro-
tene, median survival appeared to be meaningfully better than in those 
patients treated with chemotherapy alone. The biological mechanisms 
underpinning these surprising results are unclear at this time and are 
currently under investigation. Given the broad biological effects of 
rexinoids and retinoids, continued investigation of these agents in lung 
and aerodigestive tract cancers is imperative for the advancement of 
this important class of differentiating agents.
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Computed tomography (CT) stays the routine imaging procedure for 
staging patients with non-small-cell lung cancer (NSCLC) in most 
institutions. CT helps to determine resectability of the tumour and to 
assess intra- and extra-thoracic cancer spread. The success of this tech-
nique is related to the fact that CT can provide very detailed morpho-
logical information about the tumour, about the presence and enlarge-
ment of mediastinal lymph nodes and about extra-thoracic metastatic 
disease. In addition, CT is widely available and relatively non expen-
sive. However, despite the continuously improving image quality, CT 
is often not able to give an accurate answer on invasion of the tumour 
in the ﬁssure, the chest wall or the mediastinum or on the tumoral 
involvement of mediastinal lymph nodes. Furthermore, the technique 
is often not able to reliably exclude silent extra-thoracic metastases. In 
nearly all cases, TNM staging can only be adequately performed if CT 
is supplemented with another imaging technique and/or followed by a 
more invasive test. A discussion on the role of CT in staging NSCLC 
and on potential new insights that may have occurred, should therefore 
not focus on CT only, but should also include other staging techniques.
Like CT scanning, magnetic resonance (MR) imaging is an anatomical 
study. The higher density resolution and the ability of MR imaging to 
perform images in planes other than the axial plane have always been 
considered as major advantages of this technique in comparison with 
CT. However, multidetector CT (MDCT), offering high-detail refor-
matted images, has to an important degree caught up with the latter 
advantage. MR imaging currently has a limited role in the non-invasive 
staging of lung cancer but may be used to evaluate for vascular or ver-
tebral body invasion with suspected T4 tumours, to assess the integrity 
of the brachial plexus in patients with a Pancoast tumour or in speciﬁc 
situations to look for metastatic lesions.
Tumour assessment
Despite its well-known limitations, CT remains an important player in 
the T-staging of patients with NSCLC. State of the art MDCT scanners 
are indeed able to produce very detailed 2D and even 3D images of the 
tumour and its extent in the surrounding tissues. With this technique, 
invasion in the ﬁssure, the chest wall or the mediastinum can often 
be depicted with great conﬁdence. It also can deﬁnitely show that the 
tumour is too extensive for immediate resective surgery. Unfortunately 
there are still many cases where CT is not able to exactly delineate the 
tumour and its extent in the surrounding tissues. MR imaging may then 
be used as a problem-solving modality, without however being able to 
give a decisive answer in 100% of the cases. Currently MR is usually 
reserved for speciﬁc clinical situations such as the study of superior 
sulcus tumours and their extension to the chest wall. Also, in speciﬁc 
clinical situations and in experienced hands, endoscopic ultrasound and 
endobronchial ultrasound may be used as a supplementary imaging 
technique to depict for example invasion in the aorta or to evaluate 
bronchial wall invasion. 
Nodal assessment
The accuracy of CT to predict intrathoracic nodal spread of tumour re-
mains limited and the newer CT systems have not changed this. Lymph 
node enlargement ñ the consensus is to consider a node larger than 
10mm in short axis diameter as abnormal ñ remains the only indica-
tor of malignancy but is not a good indicator. The value of CT here is 
related to the fact that the technique offers a detailed roadmap of the 
lymph nodes in the hilum and the mediastinum. A very valuable supple-
mentary imaging technique for staging the mediastinum is FDG-PET. 
The value of this technique is related to its high negative predictive 
value meaning that a negative FDG-PET provides a > 90% certainty 
of absence of mediastinal lymph node metastases. According to many 
investigators this can justify skipping invasive diagnostic procedures 
and going directly to therapeutic surgery when no FDG-uptake is seen 
in the mediastinum, except when the tumour is centrally located, is 
a bronchioloalveolar carcinoma and in case of PET N1 disease. On 
